Hiren Patel

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes

Dominik Dahl, Yukiko Onishi, Paul Norwood et al. · JAMA · 2022 · 512 citations · Full text

Dual <scp>PPAR</scp>α/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental <scp>NASH</scp> models

Mukul R. Jain, Suresh Giri, Bibhuti Bhoi et al. · Liver International · 2017 · 197 citations · Full text

Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes

Julio Rosenstock, Juan P. Frías, Helena W. Rodbard et al. · JAMA · 2023 · 116 citations · Full text

Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States

Reema Mody, Qing Huang, Maria Yu et al. · Diabetes Obesity and Metabolism · 2018 · 90 citations · Full text